FDA Approves Tyenne, an Actemra Biosimilar for Autoinflammatory Diseases
source: shutterstock.com

FDA Approves Tyenne, an Actemra Biosimilar for Autoinflammatory Diseases

In early March 2024, Tyler Patchen reported that the U.S. Food and Drug Administration (FDA) approved both intravenous and subcutaneous formulations of Tyenne (tocilizumab-aazg) for use in a variety of…

Continue Reading FDA Approves Tyenne, an Actemra Biosimilar for Autoinflammatory Diseases
Celiac Disease Could Increase Risk of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
source: pixabay.com

Celiac Disease Could Increase Risk of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis

Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…

Continue Reading Celiac Disease Could Increase Risk of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
Rare Community Profiles: Kenzi’s Commitment to Raising Familial Cold Autoinflammatory Syndrome (FCAS) Awareness
Photo courtesy of Kenzi Cabrera

Rare Community Profiles: Kenzi’s Commitment to Raising Familial Cold Autoinflammatory Syndrome (FCAS) Awareness

Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Continue Reading Rare Community Profiles: Kenzi’s Commitment to Raising Familial Cold Autoinflammatory Syndrome (FCAS) Awareness
Patient Advocate Anna Ellis Discusses Rare Disease Awareness and Drug Development
source: shutterstock

Patient Advocate Anna Ellis Discusses Rare Disease Awareness and Drug Development

Contributed by Anna Ellis Every February 28, millions of people around the world participate in Rare Disease Day to raise awareness about the more than 10,000 identified rare diseases that affect…

Continue Reading Patient Advocate Anna Ellis Discusses Rare Disease Awareness and Drug Development
Adolescents with JIA Have Longer Rheumatology Wait Times
Source: https://pixabay.com/en/boy-man-sitting-thinking-waiting-1149957/

Adolescents with JIA Have Longer Rheumatology Wait Times

Adolescence is the phase which exists between childhood and adulthood; therefore, people who are between ages 10-19 are typically considered to be adolescents. How does adolescence change the way people…

Continue Reading Adolescents with JIA Have Longer Rheumatology Wait Times
Health Canada Approves Hyrimoz for Ankylosing Spondylitis
stevepb / Pixabay

Health Canada Approves Hyrimoz for Ankylosing Spondylitis

According to GlobeNewswire, Health Canada has approved of a biosimilar, Hyrimoz, to treat ankylosing spondylitis and eight other rare conditions. Sandoz Canada is excited about this approval, as it expands…

Continue Reading Health Canada Approves Hyrimoz for Ankylosing Spondylitis

Patients with Rare Autoimmune Rheumatic Disease Face More Severe COVID-19 Cases

A review of COVID-19 data from the UK shows that patients with rare autoimmune rheumatic disease (RAIRD) face a higher mortality risk, according to an article in Healio. The study,…

Continue Reading Patients with Rare Autoimmune Rheumatic Disease Face More Severe COVID-19 Cases
Researchers Provide a Better Understanding of sJIA and Still’s Disease
Sourced from publicdomainpictures.net (https://www.publicdomainpictures.net/en/view-image.php?image=275669&picture=chemical-research)

Researchers Provide a Better Understanding of sJIA and Still’s Disease

According to Healio, medical professionals from Boston Children's Hospital have conducted research that provides a better look at systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease. They looked specifically…

Continue Reading Researchers Provide a Better Understanding of sJIA and Still’s Disease
Simponi Aria (Golimumab) Approved for Juvenile Arthritis Types pJIA and jPsA
https://pixabay.com/en/baby-child-cute-doll-expression-17366/

Simponi Aria (Golimumab) Approved for Juvenile Arthritis Types pJIA and jPsA

Recently, the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen") announced the FDA approval of Simponi Aria (golimumab). The therapy is designed to treat pediatric patients (ages 2 or older)…

Continue Reading Simponi Aria (Golimumab) Approved for Juvenile Arthritis Types pJIA and jPsA
Juvenile Arthritis Awareness Month: Teen Living with Juvenile Idiopathic Arthritis Isn’t Slowing Down
source: pixabay.com

Juvenile Arthritis Awareness Month: Teen Living with Juvenile Idiopathic Arthritis Isn’t Slowing Down

According to a story from gopresstimes.com, Lily Laurent, a 13 year old student at De Pere middle school in Wisconsin, has lived with juvenile idiopathic arthritis for nine years. While…

Continue Reading Juvenile Arthritis Awareness Month: Teen Living with Juvenile Idiopathic Arthritis Isn’t Slowing Down
Ankylosing Spondylitis Treatment Approved but Not Yet Available
https://pixabay.com/en/approved-pass-ok-approval-symbol-1726357/

Ankylosing Spondylitis Treatment Approved but Not Yet Available

According to Ankylosing Spondylitis News, a new treatment, Hulio, has been approved by the FDA. It is a treatment for ankylosing spondylitis and other inflammatory disorders. Although it has been…

Continue Reading Ankylosing Spondylitis Treatment Approved but Not Yet Available
The First Treatment for Adult-Onset Still’s Disease Just Got FDA Approved
source: pixabay.com

The First Treatment for Adult-Onset Still’s Disease Just Got FDA Approved

According to a story from PR Newswire, the US Food and Drug Administration (FDA) has just approved a treatment for rare adult-onset Still's disease for the first time ever. The…

Continue Reading The First Treatment for Adult-Onset Still’s Disease Just Got FDA Approved